WO2021047437A1 - Composition pharmaceutique pour le traitement de la grippe virale et sa préparation - Google Patents

Composition pharmaceutique pour le traitement de la grippe virale et sa préparation Download PDF

Info

Publication number
WO2021047437A1
WO2021047437A1 PCT/CN2020/113105 CN2020113105W WO2021047437A1 WO 2021047437 A1 WO2021047437 A1 WO 2021047437A1 CN 2020113105 W CN2020113105 W CN 2020113105W WO 2021047437 A1 WO2021047437 A1 WO 2021047437A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
salt
active ingredient
pharmaceutical composition
oseltamivir
Prior art date
Application number
PCT/CN2020/113105
Other languages
English (en)
Chinese (zh)
Inventor
陈小新
李海军
刘卓伟
刘志强
万春喜
龙超峰
Original Assignee
广东众生睿创生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广东众生睿创生物科技有限公司 filed Critical 广东众生睿创生物科技有限公司
Priority to CN202080062567.5A priority Critical patent/CN114502150B/zh
Publication of WO2021047437A1 publication Critical patent/WO2021047437A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pharmaceutique et une préparation de celle-ci, la composition pharmaceutique contenant deux ingrédients efficaces ayant un rapport massique compris dans une certaine plage. La composition pharmaceutique présente un effet anti-virus de la grippe significativement meilleur, et après une évaluation complète, la composition pharmaceutique est considérée comme ayant de bonnes perspectives pour la préparation de médicaments.
PCT/CN2020/113105 2019-09-10 2020-09-02 Composition pharmaceutique pour le traitement de la grippe virale et sa préparation WO2021047437A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202080062567.5A CN114502150B (zh) 2019-09-10 2020-09-02 一种用于治疗病毒性感冒的药物组合物及其制剂

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910851759.3 2019-09-10
CN201910851759 2019-09-10

Publications (1)

Publication Number Publication Date
WO2021047437A1 true WO2021047437A1 (fr) 2021-03-18

Family

ID=74866856

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/113105 WO2021047437A1 (fr) 2019-09-10 2020-09-02 Composition pharmaceutique pour le traitement de la grippe virale et sa préparation

Country Status (2)

Country Link
CN (1) CN114502150B (fr)
WO (1) WO2021047437A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022089261A1 (fr) * 2020-10-29 2022-05-05 广东众生睿创生物科技有限公司 Forme cristalline d'un dérivé de pyrimidine et son procédé de préparation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103492381A (zh) * 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
CN104151312A (zh) * 2009-06-17 2014-11-19 沃泰克斯药物股份有限公司 流感病毒复制抑制剂
WO2018041263A1 (fr) * 2016-09-05 2018-03-08 广东众生药业股份有限公司 Dérivé de pyrimidine du virus de la grippe
CN108276401A (zh) * 2017-01-05 2018-07-13 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
WO2019170067A1 (fr) * 2018-03-05 2019-09-12 广东众生睿创生物科技有限公司 Forme cristalline et forme saline de composé pyridoimidazole et son procédé de préparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017133670A1 (fr) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Dérivés de pyridine et de pyrimidine et leur utilisation dans le traitement, l'atténuation des symptômes ou la prévention de la grippe
WO2018033082A1 (fr) * 2016-08-16 2018-02-22 Sunshine Lake Pharma Co., Ltd. Inhibiteurs de réplication du virus de la grippe, procédés d'application et utilisations associées

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104151312A (zh) * 2009-06-17 2014-11-19 沃泰克斯药物股份有限公司 流感病毒复制抑制剂
CN103492381A (zh) * 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
WO2018041263A1 (fr) * 2016-09-05 2018-03-08 广东众生药业股份有限公司 Dérivé de pyrimidine du virus de la grippe
CN108276401A (zh) * 2017-01-05 2018-07-13 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
WO2019170067A1 (fr) * 2018-03-05 2019-09-12 广东众生睿创生物科技有限公司 Forme cristalline et forme saline de composé pyridoimidazole et son procédé de préparation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DONALD F. SMEE, DALE L. BARNARD, STEVEN M. JONES: "Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 136, 19 October 2016 (2016-10-19), NL, pages 45 - 50, XP055485753, ISSN: 0166-3542, DOI: 10.1016/j.antiviral.2016.10.009 *
FINBERG ROBERT W, LANNO RIIN, ANDERSON DAVID, FLEISCHHACKL ROMAN, VAN DUIJNHOVEN WILBERT, KAUFFMAN ROBERT S, KOSOGLOU TEDDY, VINGE: "Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial", JOURNAL OF INFECTIOUS DISEASES, UNIVERSITY OF CHICAGO PRESS, US, vol. 219, no. 7, 15 March 2019 (2019-03-15), US, pages 1026 - 1034, XP055791527, ISSN: 0022-1899, DOI: 10.1093/infdis/jiy547 *
RANDAL A. BYRN, JONES STEVEN M., BENNETT HAMILTON B., BRAL CHRIS, CLARK MICHAEL P., JACOBS MARC D., KWONG ANN D., LEDEBOER MARK W.: "PRECLINICAL ACTIVITY OF VX-787, A FIRST-IN-CLASS, ORALLY BIOAVAILABLE INHIBITOR OF THE INFLUENZA VIRUS POLYMERASE PB2 SUBUNIT", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 59, no. 3, 1 March 2015 (2015-03-01), US, pages 1569 - 1582, XP055485823, ISSN: 0066-4804, DOI: 10.1128/AAC.04623-14 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022089261A1 (fr) * 2020-10-29 2022-05-05 广东众生睿创生物科技有限公司 Forme cristalline d'un dérivé de pyrimidine et son procédé de préparation

Also Published As

Publication number Publication date
CN114502150B (zh) 2023-03-24
CN114502150A (zh) 2022-05-13

Similar Documents

Publication Publication Date Title
US20210008072A1 (en) Formulations of azaindole compounds
JP6615755B2 (ja) インフルエンザウイルスの複製の阻害剤
AU2012276114B2 (en) Substituted cinnamamide derivative, preparation method and use thereof
TW201629004A (zh) 酚系ｔｒｐｖ１促效劑之前藥
JP2014529621A (ja) 抗炎症性の置換シクロブテンジオン化合物のコリン塩
WO2018191475A1 (fr) Polythérapies pour le traitement d'infection par le virus de la grippe
SG191964A1 (en) Orally dispersible tablet
WO2009021404A1 (fr) Hydrates d'acide (1s, 2s, 3s, 4r)-3-[(1s)-1-acétylamino-2-éthylbutyl]-4-guanidino-2-hydroxylcyclopentyl-1-carboxylique et leurs utilisations pharmaceutiques
CN104379130A (zh) 曲尼司特组合物和共结晶体
WO2005113492A1 (fr) Sels d'ambroxol analogues de cysteine, procedes d'elaboration et utilisations
CN112409379B (zh) 氘代的二氢二苯并硫杂卓化合物以及包含该化合物的药物组合物
WO2016088010A1 (fr) Compositions d'oseltamivir
JP2018515527A (ja) インフルエンザウイルスの複製の阻害剤
WO2022142731A1 (fr) Composé antiviral et son procédé de préparation
KR101902567B1 (ko) 플루오로치환된 (3r,4r,5s)-5-구아니디노-4-아세트아미도-3-(펜탄-3-일옥시)사이클로헥센-1-카복실릭 엑시드, 이의 에스테르 및 이의 용도
WO2021047437A1 (fr) Composition pharmaceutique pour le traitement de la grippe virale et sa préparation
WO2017041680A1 (fr) Composition pharmaceutique à base de vortioxétine ou d'un sel de celle-ci, et son procédé de préparation
WO2021175173A1 (fr) Composition pharmaceutique pour le traitement de la grippe et formulation contenant la composition pharmaceutique
WO2015192672A1 (fr) Dérivé de benzofurane, son procédé de préparation, et son utilisation
WO2008144956A1 (fr) Nouveaux composés ambroxol, leurs procédés de préparation et leurs utilisations
JP2017210422A (ja) 医薬組成物、医薬組成物の製造方法、及び非晶質体の安定性を向上させる方法
JPWO2019208540A1 (ja) 安定性に優れた固形製剤
TW202114678A (zh) 氮雜吲哚化合物之調配物
EP3964207A1 (fr) Composition pharmaceutique antivirale pour administration topique
CN101613343B (zh) Ⅰ晶型、ⅱ晶型的乳酸卡德沙星及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20863118

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20863118

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 26/08/2022)

122 Ep: pct application non-entry in european phase

Ref document number: 20863118

Country of ref document: EP

Kind code of ref document: A1